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[57] ABSTRACT 
The present invention relates to the use of nucleic acid 
analogues in blocking nucleic acid ampli?cation procedures 
and to diagnostic and analytical techniques based thereon. 
Also included are kits for use in the conduct of nucleic acid 
ampli?cation reactions. 
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USE OF NUCLEIC ACID ANALOGUES IN 
THE INHIBITION OF NUCLEIC ACID 
AMPLIFICATION 
This is a divisional application of Ser. No. 08/338,535, 
?led Mar. 10, 1995. 
The present invention relates to the use of nucleic acid 
analogues in blocking nucleic acid ampli?cation procedures 
and to diagnostic/analytical techniques based thereon. 
Nucleic acid ampli?cation techniques are noW in Wide 
spread use. These include the “PCR” (polymerase chain 
reaction) procedures described in EP-A-0200362 and EP-A 
0201184 Which is the technique in most Widespread use, but 
also the “LCR” (ligase chain reaction) described in EP-A 
0320308 and the so-called “NASBA” or “3SR” technique 
Which is described in “Proc. Natl. Acad. Sci. USA” Vol 87. 
pp 1874—1878 March 1990 and “Nature” Vol 350, No 6313. 
pp 91—92 Mar. 7th 1991. 
A major problem in the use of these procedures in 
diagnostics is the production of false positives by the carry 
over of ampli?ed nucleic acid sequences from previous 
reactions. As these procedures are capable of producing a 
positive result if even a single molecule containing the target 
sequence is present, it is of course very easy for such a false 
positive to occur. At present it is necessary for the reaction 
product of such procedures to be Worked up before the 
success or failure of the ampli?cation procedure can be 
determined. The involves contact betWeen the reaction prod 
uct and several pieces of laboratory equipment such as 
pipettes, as Well as With personnel Which can lead to traces 
of the ampli?cation product being available to contaminate 
future runs. 
Much effort is currently going into developing so called 
“intrinsic” procedures in Which the success of the ampli? 
cation reaction can be monitored Without any handling of the 
ampli?cation product and in an unopened reaction vessel. 
NeW forms of nucleic acid analogue are described in 
Patent Co-operation Treaty application. No. PCT/EP92/ 
01220 ?led on May 22nd 1992 Which selectively bind 
conventional nucleic acids of complementary sequence to 
form hybrids Which are more stable against dehybridisation 
by heat than are similar hybrids betWeen conventional 
nucleic acids. We have noW found that it is possible to 
exploit this greater hybrid stability to block selectively 
nucleic acid ampli?cation procedures. This technique may 
be used to prevent false positives in such ampli?cation 
procedures. It may also be exploited as an essential part of 
certain diagnostics/analytical approaches. 
In a ?rst aspect the invention provides a method of 
inhibiting a nucleic acid ampli?cation procedure comprising 
providing in said procedure an effective amount of a nucleic 
acid analogue suf?ciently complementary to a sequence of 
nucleic acid participating in an essential manner in said 
ampli?cation procedure to hybridises to said sequence suf 
?ciently strongly to prevent the effective participation of 
said sequence in the ampli?cation procedure. Thus this 
aspect of the invention includes a method of inhibiting a 
nucleic acid ampli?cation procedure in Which procedure 
each strand of a double stranded target nucleic acid has a 
region used as a template for one or more primers Which is 
or are extended or linked to form a second template comple 
mentary to said template, Wherein a nucleic acid analogue 
sufficiently complementary to a sequence of a said template 
or a said primer to hybridise thereWith is provided and 
Wherein said nucleic acid analogue hybridises suf?ciently 
strongly to the respective template or primer to block primer 
template hybridisation or to block primer extension or 
primer linking under the conditions of the procedure. 
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Preferably, said procedure is a PCR or LCR or a 3SR 
procedure. “Anchored” and “inverted” PCR procedures are 
included. 
The “double stranded target nucleic acid” Which has in 
each strand a region acting as a template is not necessarily 
a starting material, nor need it necessarily be the direct 
object of desired ampli?cation in the procedure. 
In PCR the “double stranded target nucleic acid” Will 
usually be incorporated in the starting material and it Will 
generally be the ampli?cation of at least one strand thereof 
Which is desired. HoWever, one can start a PCR reaction With 
only one DNA strand, the complementary strand being 
produced in the ?rst cycle of primer extension. In later 
cycles, the “double stranded target nucleic acid” Will be 
composed of products from previous cycles predominantly. 
In LCR, the “double stranded target nucleic acid” Will 
similarly initially normally be incorporated in the starting 
material and in later cycles Will predominantly be the 
ampli?cation product. 
It is not necessarily the case that primers are hybridised 
to each strand in the same part of the ampli?cation cycle or, 
indeed only after the double stranded target nucleic acid has 
been formed. Thus in the 3SR technique, a starting RNA 
strand is hybridised to a ?rst primer Which is extended as a 
complementary DNA strand by reverse transcriptase to form 
the “double stranded target nucleic acid” referred to. After 
destruction of the hybridised RNA strand by RNase H, a 
second primer is hybridised to the DNA strand and extended 
by reverse transcriptase to form a double stranded DNA 
molecule. Thus by this stage, both strands present in the 
DNA/RNA Will have in their time been hybridised to a 
primer Which has then been extended. 
The ?rst primer is so constructed that the DNA/DNA 
product includes a promoter for an RNA polymerase such as 
T7 RNA polymerase Which using the DNA/DNA product as 
a template produces multiple RNA copies corresponding to 
the RNA starting material, Which each in turn become 
starting materials for the ?rst primer and reverse tran 
scriptase to act upon. 
Said ampli?cation procedure may be conducted in the 
absence of said nucleic acid analogue to build-up a desired 
level of ampli?cation product and said nucleic acid analogue 
may then be added. 
Preferably the said nucleic acid analogue hybridises to 
said ampli?cation product. This Will shut doWn the ampli 
?cation and can leave the products in the form of stable 
nucleic acid—nucleic acid analogue hybrids Which are 
unable to act as templates if they contaminate a subsequent 
reaction. “Open” rather than “intrinsic” procedures are 
thereby rendered safe against carry over contamination. 
Alternatively or additionally, apparatus to be used in an 
ampli?cation procedure of said type can be treated With a 
solution containing said nucleic acid analogue to hybridise 
said analogue to any ampli?cation product Which may be 
present as a contamination, and the apparatus may be 
thereafter Washed and used in a said ampli?cation 
procedure, ampli?cation in said procedure of any ampli? 
cation product present initially as a contamination in said 
apparatus being prevented by said hybridisation to said 
analogue. 
The invention includes therefore a method of preventing 
a nucleic acid ampli?cation product from serving as a 
template in a subsequent ampli?cation procedure, Which 
method comprises hybridising thereto a nucleic acid ana 
logue Which forms thereWith a hybrid Which is stable under 
the conditions of the subsequent ampli?cation procedure. 
The invention also includes a method of preventing any 
nucleic acid ampli?cation product Which may be present in 
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an environment from serving as a contaminating template in 
a subsequent ampli?cation procedure for the nucleic acid, 
Which method comprises treating the environment With a 
nucleic acid analogue Which forms With said ampli?cation 
product a hybrid Which is stable under the conditions of said 
subsequent ampli?cation procedure. 
In practice, one may Wash all or some equipment to be 
utilised in the procedure With a solution containing the 
nucleic acid analogue, eg in a hybridisation buffer, so as to 
form a stable hybrid, betWeen the analogue and any nucleic 
acid present Which contains the target sequence for the 
ampli?cation. The hybrid formed With the nucleic acid 
analogue is suf?ciently stable to Withstand the conditions of 
the subsequent ampli?cation procedure and the contaminant 
target sequence is thereby prevented from participating in 
such a procedure to produce a false positive. 
The nucleic acid analogue for use in this and other 
aspects of the invention preferably contains from ?ve to 20 
nucleobase binding ligands eg from ten to ?fteen ligands. 
One may provide a nucleic acid analogue Which is 
tailored to halt ampli?cation of a speci?c nucleic acid 
sequence or one may provide a reagent containing a mixture 
of nucleic acid analogue sequences Which Will stop a num 
ber of different ampli?cations. Preferably, a reagent for this 
latter purpose contains a multiplicity or multitude of 
sequences. In the extreme, one may synthesise nucleic acid 
analogues using a mixture of monomer synthons (including 
ligands, complementary to each of the four DNA bases) in 
each step so as to construct molecules each containing a 
random sequence of ligands. A suf?cient quantity of such a 
reagent should contain a suf?cient number of molecules 
complementary to any ampli?cation product to be able to 
inhibit any ampli?cation procedure. 
Generally, it Will be preferred for each molecule of 
nucleic acid analogue in such a reagent to be at least a 
10-mer, more preferably at least a 12-mer, eg a 15- to 
20-mer. 
The selective blocking of ampli?cation procedures may 
be put to Work more actively as part of a diagnostic process. 
At present, When using methods such as PCR to amplify 
a sequence With a vieW to determining Whether a particular 
sequence is present, such as a single base change from an 
alternative sequence (eg a single base mutation from the 
“normal” sequence in a gene), the procedures for detecting 
the sequence in the ampli?cation product are laborious. 
These include sequencing the entire product to verify the 
presence of the altered base. They include also detecting an 
altered pattern of digestion products produced by one or 
more restriction enZymes if the change or changes in the 
gene sequence affect a restriction site. They also include 
hybridising to the product a labelled nucleic acid probe for 
the mutated sequence under conditions Which are suf? 
ciently stringent to differentiate betWeen the possible 
sequences. 
By designing a nucleic acid analogue capable of forming 
a stable hybrid With the PCR target sequence only if the 
mutation is present and providing said analogue to the 
sample nucleic acid under hybridising conditions, one may 
selectively inhibit the PCR reaction so that no exponential 
ampli?cation takes place of the mutation containing 
sequence. This principle may be extended also to other 
ampli?cation methods. 
Thus, the invention includes a method of detecting the 
presence or absence of a target nucleic acid sequence 
comprising conducting an ampli?cation procedure in Which 
each strand of a double stranded nucleic acid having a region 
used as a template including that part of said nucleic acid in 
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Which said target sequence is located if present is ampli?ed 
by hybridisation of one or more primers to said template and 
extension or linkage of said primers to form a second 
template complementary to said template, Wherein a nucleic 
acid analogue is provided Which is complementary to said 
target sequence and hybridises With a said template suf? 
ciently strongly to block said ampli?cation procedure When 
said target sequence is present but not otherWise. 
If the nucleic acid analogue is present throughout the 
ampli?cation reaction, ampli?cation of the other strand of 
the target sequence Will be linear rather than exponential so 
that no signi?cant quantities of ampli?cation product Will be 
produced. 
The presence of the target sequence may therefore be 
deduced from the failure of the ampli?cation reaction, Which 
may be PCR or LCR or 35R, to produce a signi?cant product 
level. The product of the reaction may for instance be run on 
a gel and failure to produce a band Will indicate the presence 
of the sequence. 
It Will be desirable to include an internal control to guard 
against the reaction having failed for some other reason. 
Thus, preferably as a control, a second nucleic acid substrate 
capable of ampli?cation by said ampli?cation procedure 
using the same primers is included Which undergoes ampli 
?cation to produce a product different from the product of 
ampli?cation of the target sequence. 
The procedure may be carried out in this Way to detect 
the presence of a particular base at a speci?c location, eg 
to demonstrate the presence of a speci?c single base muta 
tion. Aseries of such analyses may be conducted side by side 
or sequentially to identify Which if any of a range of possible 
mutations is present Within a gene region by using in each 
analysis a nucleic acid analogue tailored to a respective 
mutation. 
In the case of a mutation from a more common sequence, 
one may regard the mutation or the “normal” sequence as the 
“target nucleic acid sequence”. Thus if the nucleic acid 
analogue is complementary to the mutated sequence, failure 
of the ampli?cation demonstrates the presence of the muta 
tion. Alternatively, one may use a nucleic acid analogue 
complementary to the “normal” sequence, Whereupon fail 
ure of the ampli?cation Will demonstrate the presence of the 
“normal” sequence and successful ampli?cation Will shoW 
the presence of an unspeci?ed mutation, ie the absence of 
the “normal” sequence. 
Although it has been found that nucleic acid analogues 
such as the PNA’s can block a PCR ampli?cation reaction 
Whether the PNA is directed to hybridise to a PCR primer 
binding site or to a nucleotide sequence in the template 
Which is substantially removed from the. primer binding 
site, it is not the case that the choice of PNA/DNA hybridi 
sation site is immaterial. Generally, the level of affinity 
betWeen the PNA and the DNA template required to stop the 
PCR reaction is someWhat less When the PNA hybridises to 
the primer binding site or close to it. The af?nity can be ?ne 
tuned by appropriate choice of PNA sequence length taking 
into account the particular base sequence involved, homopy 
rimidine regions binding most strongly. 
Thus, it is possible to choose conditions such that tWo 
PCR reactions can be conducted on a single template 
simultaneously, one being used as a control and being 
impervious to the presence of a suitable PNA Which Will 
inhibit the other. Thus, if one employs a single forWard 
primer in combination With tWo different reverse primers, 
one producing a longer and the other a shorter ampli?cation 
product, one can direct the PNA to the binding site of the 
shorter product primer or close to it and prevent its respec 
5,972,610 
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tive PCR reaction Without simultaneously inhibiting the 
longer product PCR reaction if one chooses the af?nity of 
the PNA judiciously. If the PNA hybridisation site is one 
containing a single base pair mutation Which one Wishes to 
detect, one can arrange matters so that if the mutation is 
present PNA binds and only one PCR product is produced, 
Whilst if the mutation is absent the PNA does not bind the 
DNA strongly enough to inhibit the shorter product PCR and 
both the longer and the shorter product are produced. Thus, 
the ineffectively blocked longer product PCR acts as an 
internal control verifying the use of proper conditions in the 
assay for the presence or absence of the mutation. 
The invention includes a method Wherein the presence of 
absence of each of a plurality of sequences Within target 
nucleic acid sequence is detected in turn, by conducting a 
series of PCR ampli?cation procedures using the same 
primer or primers and providing a respective nucleic acid 
analogue in each said procedure Which is complementary to 
a respective one of said plurality of sequences to hybridise 
thereWith to block said ampli?cation procedure When said 
respective sequence is present but not otherWise. 
Thus given a target sequence having a pair of spaced 
PCR primer binding sites, one on each strand, one can 
determine Whether betWeen those sites there occurs on one 
strand a particular speci?c sequence by providing a nucleic 
acid analogue capable of binding to the speci?c sequence to 
form a hybrid thereWith Which is stable under the PCR 
conditions and Will thus block the exponential ampli?cation. 
This principle may usefully be applied to determining Which 
of a number of possible sequences are sequentially present 
in a region of nucleic acid Within a gene or a larger region 
such as a gene cluster. By Way of example, in E. Coli up to 
30 genes are clustered in a short genetic region determining 
antibiotic resistance. To determine Which antibiotic resis 
tance genes are present in a particular organism Would 
normally involve developing PCR primers for each gene of 
interest. 
Using nucleic acid analogues for selective PCR blocking, 
one can determine the genes present using a single pair of 
primers Which ?ank the entire region. Speci?c sequence 
nucleic acid analogues are made complementary to either 
strand for each gene sequence to be identi?ed and the PCR 
reaction is tried With each nucleic acid analogue in turn 
present. When a sequence in the nucleic acid is present to 
Which the analogue under test hybridises, the PCR reaction 
is blocked. Using conventional PCR, one Would need a pair 
of primers speci?c for each sequence to be investigated. 
Each primer pair Would need conditions in the ampli?cation 
to be optimised by varying a number of parameters. As 
nucleic acid analogues of the kind described in the afore 
mentioned PCT application are easily synthesised in desired 
sequences the problems of obtaining a large number of 
different PCR primers and developing ampli?cation proce 
dures suitable for each primer pair combination are over 
come. 
The invention includes a method of inhibiting the poly 
merase mediated extension of a primer hybridised to a 
nucleic acid template, comprising providing under hybrid 
ising conditions a nucleic acid analogue Which forms a 
stable hybrid With the primer or With the template at the 
primer site or doWnstream from the primer site. 
When the product of an ampli?cation procedure is to be 
sequenced or to be detected and identi?ed by probing With 
a labelled oligonucleotide, it Will normally need to be 
obtained in single stranded form. The complementary strand 
Will normally be present in equal quantities and the strands 
Will tend to recombine. It is therefore desired to conduct 
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PCR reactions in such a Way as to produce predominantly 
one of the tWo product strands (asymmetric PCR). Currently, 
this is attempted by using more of one primer than of the 
other. Ideally, exponential production of desired sequence 
takes place until one primer is exhausted and linear ampli 
?cation then results. Because of the unequal primer concen 
trations affecting the early stages of the reaction, there is 
often a problem in that the PCR process does not start 
properly. 
Therefore, the present invention includes a method of 
conducting an asymmetric nucleic acid ampli?cation proce 
dure in Which procedure each strand of a double stranded 
target nucleic acid has a region used as a template for a 
primer Which is extended to form a second template comple 
mentary to said template, in Which after a number of 
ampli?cation cycles a nucleic acid analogue is added Which 
hybridises to one of the primers suf?ciently strongly to 
inhibit the hybridisation of said primer to its target under the 
conditions of the reaction, and said procedure is then con 
tinued through a number of further cycles 
Preferably, the ampli?cation procedure is PCR. 
The invention includes conducting an asymmetric ampli 
?cation in this manner and then detecting or sequencing the 
product of the ampli?cation. 
The PNA concentration during the attempted PCR or 
other ampli?cation reaction is preferably greater than 0.5 
pM, preferably greater than 2.0 pM, most preferably more 
than 3 pM, eg 3 to 15 pM. 
The nucleic acid analogue employed in all of the above 
is preferably a peptide nucleic acid (PNA) comprising a 
polyamide backbone bearing a plurality of ligands at respec 
tive spaced locations along said backbone, said ligands 
being each independently naturally occurring nucleobases, 
non-naturally occurring nucleobases or nucleobase-binding 
groups, each said ligand being bound directly or indirectly 
to a nitrogen atom in said backbone, and said ligand bearing 
nitrogen atoms mainly being separated from one another in 
said backbone by from 4 to 8 intervening atoms. HoWever 
it may in general be any nucleic acid analogue capable of 
hybridising to a nucleic acid of complementary sequence to 
form a hybrid Which is more stable against denaturation by 
heat than a hybrid betWeen the conventional deoxyribo 
nucleotide corresponding to said analogue and said nucleic 
acid. Preferably it is a nucleic acid analogue capable of 
hybridising to a double stranded nucleic acid in Which one 
strand has a sequence complementary to said analogue, so as 
to displace the other strand from said one strand. 
The separation of the nitrogen bearing atoms in the 
backbone of peptide nucleic acids de?ned above (PNA’s) is 
preferably by ?ve atoms. In nucleic acid analogues having 
the Formula I (beloW) this has been found to provide the 
strongest af?nity for DNA. HoWever, it may in some cases 
be desired to reduce the strength of binding betWeen the 
PNA’s and DNA by spacing one or more of the ligands by 
a less than optimal spacing, eg by a spacing of more than 
5 atoms, eg by up to 14 atoms or more. 
Preferably not more than 25% of interligand spacings 
Will be 6 atoms or more. More preferably not more than 10 
to 15% of interligand spacings Will be 6 atoms or more. The 
aZa nitrogen atoms Which carry the ligands (directly or via 
linker groups) are not themselves counted in the spacings 
referred to above. 
An alternative or additional method for reducing the 
strength of DNA binding is to omit certain of the ligands, 
putting in their place a moiety Which contributes little or 
nothing to the binding of DNA, e.g. hydrogen. Preferably, 
not more than 25% of the ligand positions Will be occupied 
by non-binding moieties, e.g. not more than 10 to 15%. 
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Representative ligands include either the four main natu- may be hydroXy- or alkoXy- or alkylthio-substituted, 
rally occurring DNA bases (i.e., thymine, cytosine, adenine hydroXy, alkoXy, alkylthio, amino and halogen; and 
or guanine) or other naturally occurring nucleobases (e.g., each R3 and R4 is independently selected from the 
inosine, uracil, S-methylcytosine or thiouracil) or arti?cial group consisting of hydrogen, (C1—C4)alkyl, 
bases (e.g., bromouracil, aZaadenines or aZaguanines, etc. ) 5 hydroXy- or alkoXy- or alkylthio-substituted (C1—C4) 
attached to a peptide backbone through a suitable linker. alkyl, hydroXy, alkoXy, alkylthio and amino; 
In preferred embodiments, the nucleic acid analogues each of B1_B" is N or R3N+, Where R3 is as de?ned above; 
used in the invention have the general formula (I): each of C1_Cn is CR6R7, CHR6CHR7 or CR6R7CH2, 
Where R6 is hydrogen and R7 is selected from the group 
(I) 10 consisting of the side chains of naturally occurring 
L1 L2 L“ alpha amino acids, or R6 and R7 are independently | I | selected from the group consisting of hydrogen, 
‘r1 ‘r2 1?“ (C2—C6)alkyl, aryl, aralkyl, heteroaryl, hydroxy, 
1 2 n C —C alkoX , C —C alk lthio, NR3R4 and SR , Q\C1/B\ /G\ 2/B\D2/G _ ~ “ ‘(31/ B\Dn’I 15 gvhlere 6R3 and, R(4 1are 621s d/e?ned above, and R5 is 
hydrogen, (C1—C6)alkyl, hydroXy-, alkoXy-, or 
_ alkylthio-substituted (C1—C6)alkyl, or R6 and R7 taken 
Wherem: together complete an alicyclic or heterocyclic system; 
H is at least 2, each of D1—D” is CR6R7, CH2CR6R7 or CHR6CHR7, 
each of L1—L” is independently selected from the group 20 Where R6 and R7 are as de?ned above; 
consisting of hydrogen, hydroXy, (C1—C4)alkanoyl, each of G1—G"_1 is 
naturally occurring nucleobases, non-naturally occur 
ring nucleobases, aromatic moieties, DNA 0 
intercalators, nucleobase-binding groups and reporter —:3—C—’ 
ligands, at least one of L1—L” being a naturally occur- 25 5 
ring nucleobase, a non-naturally occurring nucleobase, — N—C—, 
a DNA intercalator, or a nucleobase-binding group; R3 
each of A1—A” is a single bond, a methylene group or a _N_(S)_ 
group of formula (Ila) or (IIb): R3 ’ 
30 
(Ha) 
I l N (S) R R — — — 
l | R3 0 
C Y C | | 35 
R2 p R2 q in either orientation, Where R3 is as de?ned above; 
Of Q is —CO2H, —CONR‘R“, —SO3H or —SO2NR‘R“ 
or an activated derivative of —CO2H or —SO3H; 
(IIb) and 
R1 R1 X 40 I is —NHR‘"R““ or —NR‘"C(O)R““, Where R‘, R“, R‘" | | H and R““ are independently selected from the group 
(I: Y (I: C_ consisting of hydrogen, alkyl, amino protecting 
R2 I R2 5 groups, reporter ligands, intercalators, chelators, 
peptides, proteins, carbohydrates. lipids, steroids, 
45 oligonucleotides and soluble and non-soluble poly 
Where: mers. Alternatively, C and D may be CHR6(CH2)S 
X is O, S, Se, NR3, CH2 or C(CH3)2; CHR7 Where S may be from 0 to 2. 
Y is a single bond, O, S or NR4; Preferred peptide nucleic acids have general formula (III): 
(III) 
L L 
I l 
o (CH2)1 O (CH2)1 
O 
Rh I (CHQkW/ N\/(CH2)11| \ N (CH2)k \H/ N\/(CH2)H,\ NH_ R 
H 
o R7 n 0 
60 
each of p and q is an integer from 1 to 5, the sum p+q Wherein: 
being not more than 10; 
each Off flnd S is Zero or an integer from 1 to 5> the Sum each L is independently selected from the group consist 
r+S belng HOI IIlOre than 10; 65 ing of hydrogen, phenyl, heterocycles, eg of one, tWo 
each R1 and R2 is independently selected from the or three rings, naturally occurring nucleobases, and 
group consisting of hydrogen, (C1—C4)alkyl Which non-naturally occurring nucleobases; 
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each R7’ is independently selected from the group con 
sisting of hydrogen and the side chains of naturally 
occurring alpha amino acids: 
n is an integer from 1 to 60; 
each of k, l and m is independently Zero or an integer from 
1 to 5; preferably the sum of k and m is 1 or 2, most 
preferably 1; 
Rh is OH, NH2 or —NHLysNH2; and 
Ri is H or COCH3. 
Particularly preferred are compounds having formula (III) 
Wherein each L is independently selected from the group 
consisting so the nucleobases thymine (T), adenine (A), 
cytosine (C), guanine (G) and uracil (U), in particular 
thymine, and n is an integer from 1 to 30, in particular from 
4 to 20. 
The peptide nucleic acids of the invention may be syn 
thesiZed by adaptation of standard peptide synthesis 
procedures, either in solution or on a solid phase. The 
synthons used may be specially designed monomer amino 
acids or their activated derivatives, protected by standard 
protecting groups. The oligonucleotide analogues also can 
be synthesiZed by using the corresponding diacids and 
diamines. 
Thus, the monomer synthons used to produce compounds 
for use on the invention may be selected from the group 
consisting of amino acids, diacids and diamines having 
general formulae: 
(IV) 
(V) 
(VI) 
Wherein L, A, B, C and D are as de?ned above, except that 
any amino groups therein may be protected by amino 
protecting groups; E is COOH, CSOH, SOOH, SOZOH or an 
activated derivative thereof; and F is NHR3 or NPgR3, 
Where R3 is as de?ned above and Pg is an amino protecting 
group. 
Preferred monomer synthons are amino acids having 
formula (VII): 
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(VII) 
HOOC YNWNH, 
or amino-protected and/or acid terminal activated deriva 
tives thereof, Wherein L is selected from the group consisting 
of hydrogen, phenyl, heterocycles, naturally occurring 
nucleobases, non-naturally occurring nucleobases, and pro 
tected derivatives thereof; and R7’ is independently selected 
from the group consisting of hydrogen and the side chains of 
naturally occurring alpha amino acids. Especiallyv preferred 
are such synthons having formula (4) Wherein R is hydro 
gen and L is selected from the group consisting of the 
nucleobases thymine (T), adenine (A), cytosine (C), guanine 
(G) and uracil (U) and protected derivatives thereof. 
The production of such PNA’s is described in detail in 
PCT application No. PCT/EP92/01220 referred to above. 
This invention includes a kit for use in the conduct of a 
nucleic acid ampli?cation reaction comprising a plurality of 
primers for said ampli?cation and at least one nucleic acid 
analogue Which has a sequence complementary to a 
sequence in one of said primers or to a target nucleic acid 
sequence to be ampli?ed using said primers in said ampli 
?cation reaction. 
Such a kit may further comprise a polymerase or ligase for 
use in said ampli?cation reaction to produce extension or 
ligation of said primers, e.g. a DNA polymerase such as Taq 
polymerase. 
For use in a “35R” type of procedure, the kits may further 
include any one or more of a reverse transcriptase, an RNA 
polymerase and a nuclease such as RNase H. 
Generally, such kits may further include nucleotides, 
(some or all of dTTP, dCTP, dATP and dGTP), one or more 
of Which may be labelled in any knoWn or suitable manner, 
e.g. radio labelled. Reagents for detecting such labels may 
be included. Kits may further include one or more of buffers, 
salts, stabilising agents and nucleic acid recognition agents. 
These may be reagents Which recognise speci?c sequences 
or reagents Which recognise nucleic acids in a non-sequence 
speci?c manner, example of the former being oligonucle 
otides or nucleic acid analogues of the PNA type, optionally 
bearing detectable labels, and of the latter being antibodies 
to nucleic acids. 
Suitable labels for use in the invention include radio 
isotope labels, enZyme labels, biotin, spin labels, 
?uorophores, chemiluminescence labels, antigen labels and 
antibody labels. 
Kits may further include reagents for conducting a posi 
tive control experiment including a template for ampli?ca 
tion using said primers to produce an ampli?cation product 
different from that of said nucleic acid ampli?cation reac 
tion. 
A kit may further include reagents for use in sequencing 
a nucleic acid ampli?cation product, e.g. polymerase such as 
Taq polymerase and one or more dideoxynucleotides. 
In the folloWing examples, the PNAs all have a backbone 
derived from monomer synthons of Formula VII and in each 
case each L is one of the naturally occurring nucleobases 
represented in the usual Way by A, C, G or T. The nomen 
clature employed folloWs that used in PCT No. PCT/EP92/ 
01220 referred to above. 
5,972,610 
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The invention Will be further illustrated by the following 
speci?c examples in Which reference is made to the attached 
drawings in Which: 
FIG. 1 is an autoradiograph of a gel shoWing inhibition of 
polymerase mediated extension of a primer by PNA; 
FIG. 2 is an ethidium bromide gel shoWing selective 
blocking of PCR reactions by PNA’s discriminating 
betWeen sequences differing by a single base pair; 
FIG. 3 is an ethidium bromide gel shoWing a further 
example of PNA directed inhibition of PCR; 
FIG. 4 is an ethidium bromide gel shoWing inhibition of 
PCR by PNA directed at sites on the PCR template Which 
overlap With or are spaced by varying amounts from the 
primer target site; and 
FIG. 5 is an ethidium bromide gel shoWing complete 
inhibition of a PCR reaction by PNA complementary to one 
primer; and 
FIG. 6 is an ethidium bromide gel shoWing the result of 
Example 6 further illustrating PCR inhibition to identify a 
single base change. 
EXAMPLE 1 
Primer Extension Arrest by PNA 
0.5 pg of a plasmid (Bluescript, Strategene, Inc) contain 
ing an inserted sequence of 10 thymine residues (pTIOKS) 
cleaved With the restriction endonuclease PvuII, and 0.1 pg 
“reverse primer” (5 ‘-AAC AGC TAT GAC CAT G) to Which 
Was added 1 pl 10>< concentrated buffer (for E. Coli KlenoW 
DNA polymerase: 100 mM Tris-HCl, 100 mM MgCl2, 50 
mM NaCl, 1 mM dithiothreitol (DTT), pH 7.5, for Taq DNA 
polymerase: 100 mM Tris-HCl, 15 mM MgCl2 500 mM 
NaCl, 1 mg/ml gelatine, pH 8.3) and 6 pl H20 and 100 ng 
of A10 PNA complementary to the T10 insert in the plasmid 
Was incubated for 10 mins at 90° C., 60 mins at 37° C. and 
then cooled to 20° C. Then 1 pl of 10 mM DTT, 1 pl of 10 
pM solution of dCTP, dGTP, dTTP, and 1 pCi (x32p-dATP 
and 1 U of the appropriate DNA polymerase Was added. 
After 5 mins at 20° C. 2 pl of a 1 mM solution of dAT P, 
dCTP, dGTP and dTTP Was added and incubation Was 
continued for 15 mins at 37° C. for E. coli DNApolymerase 
or 60° C. for Taq polymerase. The DNA Was subsequently 
precipitated by addition of 50 pl ethanol, 2% (W/v) potas 
sium acetate and analysed by electrophoresis in 8% (W/v) 
acrylamide/7M urea sequencing gel folloWed by autorad 
iography. The result is shoWn in FIG. 1, the lanes represent 
ing the folloWing: 
Lane 1: E. coli DNA polymerase KlenoW fragment, no 
PNA. 
Lane 2: as lane 1 but in the presence of PNA. 
Lane 3: Taq polymerase, no PNA. 
Lane 4: Taq polymerase in the presence of PNA. 
Lane 5: control With plasmid cleaved With BamH1. 
It can be seen from the diagram that the A10 PNA should 
hybridise to one strand of the template DNA adjacent the 
Barn HI site. Thus if the A10 PNA blocks polymerase 
extension of the primer, products should be produced Which 
run on the gel With the Barn H1 cleavage products seen in 
lane 5. If polymerase extension is unchecked by PNA, 
longer extension products should be obtained. it can be seen 
that in each PNA containing lane (2 and 4) the expected band 
in the Barn Hl position is produced. In the absence of PNA, 
a longer product is seen Which is substantially Wholly absent 
in the PNA/Taq lane (lane 4) shoWing complete blocking of 
Taq by the PNA. 
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EXAMPLE 2 
Detection of Single Base Mutation by PNA directed Inhi 
bition of PCR DNA Ampli?cation. 
The plasmid pT10KS Was constructed by cloning the 
complementary oligonucleotides 5‘-GATCCT1OG and 
5 ‘-GATCCA,1OG into respective strands at the BamHI site of 
the Bluescript KS+plasmid (Stratagene). The plasmid 
pT9CKS Was constructed by cloning the complementary 
oligonucleotides 5‘-TCGACT5CT4G and 
5‘-TCGACA4GA5G into the SalI site of pUCl9. 
Apolymerase chain reaction (PCR) Was conducted Which 
contained 25 ng plasmid 1, 25 ng plasmid 2 DNA, 1.25 mM 
DATP, 1.25 mM dCTP, 1.25 mM dGTP, 1.25 mM dTTP, 0.2 
pg primer 1, 0.2 pg primer 2, and 2.5 pg PNA in 50 pl buffer 
(10 mM Tris-HCl, 3.5 mM MgCl2, 50 mM KCl, 0.1 mg/ml 
gelatine, pH 8.3). The sample Was heated to 94°C. for 5 
mins, cooled to 65° C., at Which stage 1 U of Taq DNA 
polymerase (Boehringer Mannheim) Was added. Subse 
quently 30 temperature cycles (94° C. (2 mins), 40° C. (3 
mins) and 65° C. (2 mins)) Were run. 
The resulting DNAWas analysed by electrophoresis in 6% 
(W/v) polyacrylamide gels run in TBE buffer (90 mM 
Tris-borate, 1 mM EDTA, pH 8.3) and the DNA Was 
visualised by staining With ethidium bromide. 
The experiment Was performed as described in Example 
1 using “M13 primer” as primer 1 and “reverse primer” as 
primer 2. The resulting gel appears in FIG. 2. The folloWing 
plasmids and PNAs Were used: 
Lane 1: pT9CKS (pBluescriptKS+ in Which dA5GA4/ 
dT4CT5 PNA target Was cloned into the Sal I site) and 
pT10KS (pBluescriptKS+in Which a dAlo/dTloPNA 
target Was cloned into the Barn H1 site), no PNA. 
Lane 2: as lane 1 but With PNA H-T5CT4LysNH2. 
Lane 3: as lane 1 but With PNA H-T1OLysNH2. 
Lane 4: pT10KS and pT9CKS With PNA H-T5CT4 
LysNH2. 
Lane 5: pT10KS and pT9CKS With PNA H-T1OLysNH2. 
In lane 1, tWo PCR products are clearly seen, one from 
each plasmid. Ampli?cation of pT10Ks gives a 118 bp 
fragment and ampli?cation of pT9CKS gives a 221 bp 
fragment. 
Plasmid pT9CKS contains a target sequence for PNA 
T5CT4LysNH2. In lane 2 one sees no band for this plasmid 
shoWing inhibition of the PCR by the PNA. 
EXAMPLE 3 
Further Demonstration of PNA Directed Inhibition of PCR 
The PNA Tlo-LysNH2 Was synthesiZed as in Egholm, M., 
Buchardt, O., Nielsen, P. E. and Berg, R. H. (1992) J. Amer. 
Chem. Soc. 114, 1895—1897 and Egholm, M., Buchardt, O., 
Nielsen, P. E. and Berg, R. H. (1992) J. Amer. Chem. Soc. 
114, 9677—9678. The plasmids pT10KS and pT9CKS Were 
as described in Example 2. The control plasmid PCKS Was 
constructed by cloning a 99 bp PCR fragment (With no target 
sites for any of the PNSa used in this example) into the SmaI 
site of the bluescript KS+plasmid. Using standard tech 
niques plasmids Were isolated from selected clones of 
recombinant E Coli JM103, puri?ed by buoyant density 
centrifugation in CsC1 gradients and sequenced by the 
dideoxy method. 
The folloWing oligonucleotide primers Were used in the 
PCR reactions: reverse primer (5‘ 
CACACAGGAAACAGCTATGAC)SEQ ID NO:2 and for 
Ward primer (5‘-GTAAAACGACGGCCAGT)SEQ ID 
NO:3. PCR ampli?cations Were carried out in a 50 pl 
volume containing 1 ng of each plasmid, 0.2 pM of each 
primer, 200 pM dNTP, 10 mM Tris-HCl, pH 8,3 (at 25° C.), 
10 mM KCl, and 3 mM MgCl2. 
5,972,610 
13 
The PCR reactions Were overlain With 2 drops of paraf?n 
oil and incubated at 90° C. for 2 minutes before the 
ampli?cation process Were initiated by the addition of 3 U 
of the stoffel polymerase (Perkin Elmer Cetus). A LEP 
ampli?er machine (IgG Biotech) Was used in all experiments 
and PCR cycle pro?les Were 96° C., 2 min—55° C., 3 
min—35° C., 1 min—65° C., 2 min—35 cycles. 
To ensure that the formation of the PNA/DNA complexes 
preceded PCR primer binding and extension the normal 3 
step PCR cycle Was expanded With a distinct PNA annealing 
step at a temperature Well above the Tm of the PCR primers. 
FIG. 3 shoWs the experimental set-up and result of PCR 
inhibition in the presence of PNA T10-LysNH2. The tWo 
plasmid templates described above Were used, namely the 
pT10KS plasmid Which directs the ampli?cation of a 246 bp 
fragment containing an A1O target site and the control 
plasmid, pCKS, Which directs the ampli?cation of a 329 bp 
non-target fragment. When the PNA T10-LysNH2 is absent 
(lane 2) the pT10KS plasmid directs the synthesis of the 
expected 246 bp PCR fragment. In the presence of 3.2 pM 
PNA T10-LysNH2, hoWever, no product is produced (lane 3 
to 5). The absence of product is not due to a non-speci?c 
inhibitory effect of PNA Tlo-LysNH2 on the PCR reaction, 
since PNA Tlo-LysNH2 Will not inhibit the ampli?cation of 
the expected 329 bp fragment from the pCKS control 
plasmid (lane 1). Thus, it is seen that the PNA TloLysNH2 
can prevent the ampli?cation of its cognate target DNA in a 
sequence speci?c manner. 
EXAMPLE 4 
Demonstration that the relative position of the PNA and 
PCR primer target sites can be changed Without affecting 
inhibition 
This example shoWs the effects obtained Where the PNA 
target site is (1) located in the middle of the PCR region, is 
(2) located immediately adjacent to a PCR primer site or (3) 
overlaps one of the PCR primer sites. There are fundamental 
differences betWeen the underlying mechanisms of inhibi 
tion in these three cases. When the PNA target site is located 
at a distance from the PCR primer sites inhibition is 
expected to operate by preventing read-through by the 
polymerase. Conversely, inhibition is expected to operate by 
primer exclusion When the PNA and PCR primer target sites 
overlap. Finally, When the PNA target is located adjacent to 
the PCR primer site, inhibition is likely to operate by either 
preventing polymerase access to the PCR primer and/or by 
preventing initiation of primer elongation. In all three cases 
ef?cient inhibition can be obtained With PNA Tlo-LysNH2 
as shoWn in FIG. 4. In this Example, PCR is attempted 
using, in respective runs, three different forWard primers, 
referred to as “forWard primer”, “SK primer” and “A10 
primer”. These are forWard primer (5‘ 
GTAAAACGACGGCCAGT)SEQ ID NO: 3, T10 primer 
(5‘-CATCCTTTTTTTTTTG) SEQ ID NO: 4 and SK primer 
(5‘-TCTAGAACTAGTGGATC)SEQ ID NO: 5. In plasmid 
pT10 KS used in this example (see Example 2 for details) 
the 3‘-end of the forWard primer target site is located 101 bp 
doWnstream of the A10 target, the 3‘-end of the SK primer 
is located immediately doWnstream of the A10 target and the 
A10 primer spans the A10 target site including 5 and 1 bp 
on the 5‘- and 3‘-side, respectively. Lanes 1—2: shoW ampli 
?cation of the pT10KS plasmid With reverse and forWard 
primers in the absence (1) or presence of 3.2 pM (2) of 
PNA-T1O-LysNH2. Lanes 3 and 4: shoW ampli?cation of the 
pT10KS With reverse and SK primers in the absence (3) or 
presence (4) of 3.2 pM of PNA T1O-LysNH2. Lanes 7 and 8: 
shoWs ampli?cation of the pT10KS plasmid With reverse 
and T10 primers in the absence (7) or presence (8) of 3.2 pM 
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of PNA Tlo-LysNH2 PCR cycle conditions Were 96° C., 2 
min—55° C., 3 min—35° C., 1 min—65° C., 2 min—35 
cycles. PNA TloLysNH2 Will prevent formation of a PCR 
product from templates With Widely spaced PNA and PCR 
primer target sites (lane 2), adjacent PNA and PCR primer 
target sites (lane 4) and overlapping PNA and PCR primer 
target sites (lane 8). 
EXAMPLE 5 
A PCR reaction Was carried out generally as described in 
Example 2 in the absence and presence of a PNA comple 
mentary to one primer. 
The results are shoWn in FIG. 5. In lane 1, the expected 
PCR product is seen. In lane 2, the PCR reaction is shoWn 
to be entirely inhibited. 
The example Was carried out using “M13 primer” as 
primer 1 and GATCC TloG as primer 2. The target plasmid 
Was pTloKS. The temperatures used in the second phase of 
each of the 30 cycles Was 35° C. instead of 40° C. 
EXAMPLE 6 
PCR Inhibition With Mixed Sequence PNAs 
The PNAs used in the previous examples contained only 
pyrimidine residues and have been shoWn to form triplexes 
With their target sequences. Thus, to shoW the generality of 
the principle a series of experiments Were conducted With 
mixed sequence PNAs forming standard Watson-Crick 
duplexes With their target DNAS. FIG. 6 shoWs the experi 
mental setup and result of single base mutation analysis With 
tWo mixed sequence PNAs differing by a single nucleotide 
(PNA-A: H-TTCCGGITGCC—NH2 and PNA-B: Gly 
TTCCGGQTGCC—NH2). TWo templates are used (“A” and 
“B”) containing the corresponding point mutation. Three 
oligonucleotide primers are involved in this experiment. A 
forWard and reverse oligo pair Which produce a 750 bp PCR 
fragment and a degenerate primer directed against the region 
containing the point mutation. Together With the forWard 
primer the degenerate primer directs ampli?cation of a 150 
bp fragment using either the A or B allele as template. The 
PNAs are directed against the region containing the point 
mutation and clamping is thus expected to operate by primer 
exclusion. 
In this example, each PCR reaction (50 pl) contains 200 
pM dNTP, 10 mM Tris-HCl pH 9.9 (20° C.), 50 mM KCl, 
1.5 mM MgCl2, 0.01% gelatine, 0.1% Triton X-100, 1 U 
supertag enZyme (Stratagene) 1 ng of allele speci?c plasmid, 
10 pmol of degenerate primer directed against the region 
containing the mutation, 10 pmol of forWard primer, 10 
pmol of reverse primer and PNAs as indicated. In the ?gure, 
the lanes are as folloWs: Lane 1: A-allele and no PNA. Lane 
2: A-allele and 10 pM PNA-A. Lane 3: A-allele and 10 pM 
PNA-B. Lane 4: B-allele and no PNA. Lane 5: B-allele and 
10 pM PNA-A. Lane 6: B-allele and 10 pM PNA-B. PCR 
conditions Were 96° C. 1 min—60° C. 2 min—40° C. 30 
sec—60° C. 2 min—30 cycles. 
When the A-allele is used as template both the 750 bp 
(internal PCR control) and the 150 bp fragment (diagnostic 
of the allele) is produced in the absence of PNA-A (lane 1). 
When the reaction contains PNA-A, hoWever, only the 750 
bp PCR control fragment is produced (lane 2). In contrast, 
both the 750 bp and 5bp PCR fragments are produced in the 
presence of PNA-B (lane 3). Changing the template to the 
B-allele reverses the results. Thus, the presence of PNA-B 
Will inhibit the production of the 150 bp fragment (lane 6) 
Whereas the presence of PNA-A Will not (lane 5). Thus, We 
conclude that both mixed sequence PNAs (A and B) are able 
to inhibit their cognate PCR product With point mutation 
accuracy. 
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SEQUENCE LISTING 
SEQ ID NO 1 
LENGTH: 16 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
<400> SEQUENCE: l 
aacagctatg accatg 
SEQ ID NO 2 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
<400> SEQUENCE: 2 
cacacaggaa acagctatga c 
SEQ ID NO 3 
LENGTH: 17 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
<400> SEQUENCE: 3 
gtaaaacgac ggccagt 
SEQ ID NO 4 
LENGTH: 16 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
<400> SEQUENCE: 4 
catccttttt tttttg 
SEQ ID NO 5 
LENGTH: 17 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
<400> SEQUENCE: 5 
tctagaacta gtggatc 
OTHER INFORMATION: Description of Artificial Sequence: 
OTHER INFORMATION: Description of Artificial Sequence: 
Primer. 
Primer. 
21 
OTHER INFORMATION: Description of Artificial Sequence: Primer. 
17 
OTHER INFORMATION: Description of Artificial Sequence: Primer. 
16 
OTHER INFORMATION: Description of Artificial Sequence: Primer. 
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We claim: 
1. A method of inhibiting a nucleic acid ampli?cation 
procedure, in Which ampli?cation procedure each strand of 
a double-stranded target nucleic acid has a region used as a 
?rst template for at least one primer Which linked to another 
primer or eXtended With nucleotides to form a second 
template Which is complementary to said ?rst template, said 
method comprising 
hybridizing a nucleic acid analogue to a sequence of said 
?rst template or said at least one primer to inhibit 
linking or extension of the at least one primer during 
performance of the ampli?cation procedure. 
55 
65 
2. The method of claim 1, Wherein the hybrid formed 
betWeen the nucleic acid analogue and the sequence of said 
?rst template or said at least one primer is more stable 
against heat denaturation than a hybrid betWeen a conven 
tional nucleic acid corresponding to the nucleic acid ana 
logue and the sequence of said ?rst template or said at least 
one primer. 
3. The method of claim 1, Wherein the ampli?cation 
procedure is a PCR or an LCR procedure. 
4. The method of claim 1, further comprising, before said 
hybridizing step, conducting said ampli?cation procedure in 
the absence of said nucleic acid analogue to accumulate 
ampli?cation product. 
5,972,610 
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5. The method of claim 4, wherein said nucleic acid 
analogue hybridiZes to said ampli?cation product. 
6. Amethod of inhibiting ampli?cation of a contaminating 
nucleic acid in an ampli?cation procedure conducted using 
an ampli?cation apparatus, in Which ampli?cation procedure 
each strand of a double-stranded nucleic acid has a region 
used as a ?rst template for at least one primer Which is linked 
to another primer or extended With nucleotides to form a 
second template Which is complementary to said ?rst 
template, said method comprising 
contacting a solution containing a nucleic acid analogue 
With said ampli?cation apparatus to hybridize said 
nucleic acid analogue to any nucleic acid Which may be 
present as a contamination to inhibit linking or exten 
sion of the contaminating nucleic acid during perfor 
mance of the ampli?cation procedure; 
thereafter Washing the ampli?cation apparatus; and 
thereafter conducting said ampli?cation procedure using 
said ampli?cation apparatus, Wherein ampli?cation of 
the contaminating nucleic acid is inhibited by the 
hybridiZing step. 
7. The method of claim 6, Wherein the hybrid formed 
betWeen the nucleic acid analogue and the contaminating 
nucleic acid is more stable against heat denaturation than a 
hybrid betWeen a conventional nucleic acid corresponding to 
the nucleic acid analogue and the contaminating nucleic 
acid. 
8. A method of preventing a nucleic acid ampli?cation 
product from serving as a template in a subsequent ampli 
?cation procedure, in Which subsequent ampli?cation pro 
cedure each strand of a double-stranded nucleic acid has a 
region used as a ?rst template for at least one primer Which 
is linked to another primer or extended With nucleotides to 
form a second template Which is complementary to said ?rst 
template, said method comprising 
hybridiZing a nucleic acid analogue to the nucleic acid 
ampli?cation product to inhibit linking or extension of 
said ampli?cation product during performance of the 
subsequent ampli?cation procedure. 
9. The method of claim 8, Wherein the hybrid formed 
betWeen the nucleic acid analogue and the nucleic acid 
ampli?cation product is more stable against heat denatur 
ation than a hybrid betWeen a conventional nucleic acid 
corresponding to the nucleic acid analogue and the nucleic 
acid ampli?cation product. 
10. A method of inhibiting ampli?cation of a contaminat 
ing nucleic acid in a subsequent ampli?cation procedure 
conducted in an environment, in Which subsequent ampli 
?cation procedure each strand of a double-stranded nucleic 
acid has a region used as a ?rst template for at least one 
primer Which is linked to another primer or extended With 
nucleotides to form a second template Which is complemen 
tary to said ?rst template, said method comprising 
contacting a nucleic acid analogue With the environment 
to hybridiZe said nucleic acid analogue to any nucleic 
acid Which may be present as a contamination to inhibit 
linking or extension of the at least one primer during 
performance of the subsequent ampli?cation proce 
dure; and 
thereafter conducting the subsequent ampli?cation 
procedure, Wherein ampli?cation of the contaminating 
nucleic acid is inhibited by the hybridiZing step. 
11. The method of claim 10, Wherein the hybrid formed 
betWeen the nucleic acid analogue and the contaminating 
nucleic acid is more stable against heat denaturation than a 
hybrid betWeen a conventional nucleic acid corresponding to 
the nucleic acid analogue and the contaminating nucleic 
acid. 
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12. A method of detecting the presence or absence of a 
target nucleic acid sequence, comprising 
(a) conducting an ampli?cation procedure using (1) a 
double-stranded nucleic acid comprising a nucleic acid 
region, Which nucleic acid region may contain the 
target nucleic acid sequence, (2) at least one primer, 
and (3) a nucleic acid analogue comprising a sequence 
Which is complementary to said target nucleic acid 
sequence, Wherein 
When the target nucleic acid sequence is present, then 
the nucleic acid analogue hybridiZes With the target 
nucleic acid sequence to inhibit the at least one 
primer from linking to another primer or extending 
With nucleotides during performance of the ampli? 
cation procedure, or 
When the target nucleic acid sequence is absent, then 
the at least one primer hybridiZes With the nucleic 
acid region and is linked to another primer or 
extended With nucleotides to form an ampli?cation 
product; and 
(b) determining the presence or absence of ampli?cation 
product to detect the presence or absence of the target 
nucleic acid sequence. 
13. The method of claim 12, Wherein the hybrid formed 
betWeen the nucleic acid analogue and the target nucleic acid 
sequence is more stable against heat denaturation than a 
hybrid betWeen a conventional nucleic acid corresponding to 
the nucleic acid analogue and the target nucleic acid 
sequence. 
14. The method of claim 12, Wherein the target nucleic 
acid sequence, if present, is betWeen a pair of primer binding 
sites, and the method comprises sequentially detecting the 
presence or absence of each of a plurality of sequences 
Within the target nucleic acid sequence by conducting a 
series of ampli?cation procedures using the same primers 
and different nucleic acid analogues for each of the series, 
each of Which is complementary to a different one of the 
plurality of sequences, and determining Whether ampli?ca 
tion of each of the plurality of sequences has occurred to 
detect the presence or absence of the each sequence. 
15. The method of claim 12, Wherein the conducting step 
(a) further comprises including a control nucleic acid Which 
undergoes ampli?cation using the same at least one primer, 
to produce a second ampli?cation product Which is distin 
guishable from the ampli?cation product comprising the 
nucleic acid region, and the determining step (b) further 
comprises determining the second ampli?cation product. 
16. A method of conducting an asymmetric nucleic acid 
ampli?cation procedure, comprising 
providing a double-stranded nucleic acid, Wherein each 
strand of the double-stranded nucleic acid has a region 
used as a ?rst template for a ?rst primer Which is 
extended With nucleotides to form a second template 
Which is complementary to said ?rst template; 
amplifying the double-stranded nucleic acid for a number 
of ampli?cation cycles to produce ampli?cation prod 
uct; 
combining the ampli?cation product With a nucleic acid 
analogue Which hybridiZes to the ?rst primer to inhibit 
extension of the ?rst primer With nucleotides during 
performance of further ampli?cation cycles, and 
continuing the ampli?cation procedure for the further 
ampli?cation cycles. 
17. The method of claim 16, Wherein the hybrid formed 
betWeen the nucleic acid analogue and the ?rst primer is 
more stable against heat denaturation than a hybrid betWeen 
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a conventional nucleic acid corresponding to the nucleic 
acid analogue and the ?rst primer. 
18. A method of inhibiting a polymerase-mediated exten 
sion procedure of a primer Which is hybridized tc a nucleic 
acid template, comprising 
providing an extension procedure reaction mixture com 
prising a nucleic acid template, a primer and a poly 
merase; and 
combining With the mixture a nucleic acid analogue 
Which hybridiZes to the primer or the nucleic acid 
template to inhibit extension of the primer With nucle 
otides during performance of the extension procedure. 
19. The method of claim 18, Wherein the hybrid formed 
betWeen the nucleic acid analogue and the primer or the 
nucleic acid template is more stable against heat denatur 
ation than a hybrid betWeen a conventional nucleic acid 
corresponding to the nucleic acid analogue and the primer or 
the nucleic acid template. 
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20. The method of claim 1, Wherein the 
analogue comprises a peptide nucleic acid. 
21. The method of claim 6, Wherein the 
analogue comprises a peptide nucleic acid. 
22. The method of claim 8, Wherein the 
analogue comprises a peptide nucleic acid. 
23. The method of claim 10, Wherein the 
analogue comprises a peptide nucleic acid. 
24. The method of claim 12, Wherein the 
analogue comprises a peptide nucleic acid. 
25. The method of claim 16, Wherein the 
analogue comprises a peptide nucleic acid. 
26. The method of claim 18, Wherein the 
analogue comprises a peptide nucleic acid. 
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